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Abstract 
Diosgenin,  a  traditional  Yam  extraction,  has  been  used  in  hormone  replacement  for 
menopausal women. We aimed to investigate the influences of diosgenin administration 
upon the MMP-2 and -9 activity and expression and reproductive hormones of ovariec-
tomized (OVX) rats, a model of menopausal status. Seven-week old female Wistar rats 
with bilateral OVX or sham operation (controls) were divided and administered different 
dosages of diosgenin (0, 10, 50, or 100 mg/kg/day) for 8 weeks. Serum was then sampled 
for progesterone (P4) and estradiol (E2) assay and uterine horns harvested. Myometrial 
MMP-2 and -9 activity and expression were surveyed and myometrial collagen expres-
sion was also assayed. The results show higher body weight in OVX rats across the 8 
weeks post surgery and no significant differences were noted among OVX or Sham rats 
with diosgenin supplements. There were lower P4 and E2 concentrations in OVX rats 
compared to Sham rats, and higher P4 concentration of Sham rats post diosgenin sup-
plement. MMP-2 and -9 mRNA expression and activity was lower in OVX rats, although 
higher MMP-2 and lower MMP-9 activity/mRNA expression was observed in OVX rats 
post diosgenin supplementation. Collagen mRNA expression was higher in OVX rats 
compared to Sham controls, and diosgenin administration decreased collagen mRNA 
expression in OVX rats. In conclusion, diosgenin is associated with gelatinase expression 
and collagen metabolism in OVX rats. Diosgenin administration can partially reverse the 
effects of OVX upon MMP functions and hormone status. Adequate diosgenin supple-
ment  might  modulate  myometrial  gelatinase  expression  and  collagen  metabolism  in 
menopausal subjects. 
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Introduction 
Hormone replacement therapy (HRT) is one of 
the most commonly prescribed medicines for meno-
pausal  women.  Estrogen  replacement  therapy  can 
decrease the risk of developing numerous disorders, 
including  osteoporosis  [1],  Alzheimer's  disease  [2], 
vasomotor symptoms [3], cardiovascular diseases [4], 
etc.  Synthetic  estrogen,  the  current  most  effective 
agent for HRT, is widely used in menopausal women. 
However, several studies suggest that traditional HRT 
is  not  effective  in  reducing  the  risk  of  some  meno-
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pause-related  disorders  [5,  6].  Therefore,  many  pa-
tients  seek  alternative  modalities  for  symptomatic 
relief. The requests for complementary or alternative 
therapies  for  hormone  replacement  have  increased 
substantially. One of the current popular treatments is 
wild yam. Wild yam or diosgenin (extracted from the 
root of wild yam) has been widely used for alternative 
HRT [7, 8].  
Many menopausal women use traditional herb 
medicines, such as wild yam extract or diosgenin, to 
restore  gonadal  hormones  and  therefore  minimize 
post-menopausal  symptoms.  Yam  is  composed  of 
some  steroidal  saponins,  which  may  influence  en-
dogenous steroidogenesis [9]. Administration of yam 
was  reported  to  increase  the  status  of  sexual  hor-
mones,  lipids,  and  antioxidants  in  postmenopausal 
women [10]. Diosgenin, one type of steroidal saponin, 
is extracted from the root of wild yam and has been 
used  in  numerous  medical  applications.  It  was  re-
ported  that  short-term  treatment  with  diosgen-
in-enriched  yam  extract  in  women  suffering  from 
menopausal symptoms is free of side-effects, but ap-
pears to have little effect on menopausal symptoms 
[9]. However, the results from animal models show 
that diosgenin supplementation could affect the kid-
ney  and  adrenal  gland  functions,  and  improve  the 
epidermal thickness in ovariectomized (OVX) rats [8, 
11, 12]. As a result, it was proposed that  diosgenin 
supplementation would stimulate the production of 
ovarian hormones in OVX rats. Endometrial function 
is known to be influenced by the ovarian hormones, 
estradiol  and  progesterone.  Ovarian  hormones  and 
function are closely associated with endometrial and 
uterus statuses. However, the mechanisms by which 
the lack of ovarian hormone influences the molecular 
biology of uterus are poorly understood.  Moreover, 
the effects of wild yam or diosgenin upon menopausal 
individuals  remain  obscure.  Information  about  the 
efficacy  and  pharmacodynamics  for  these  natural 
medicines upon menopausal individuals are lacking.  
Matrix metalloproteinases (MMPs), a family of 
zinc-dependent  proteinases,  are  essential  for  some 
physiological  and  pathological  processes,  such  as 
wound  repair  [13],  cardiovascular  diseases  [14], 
rheumatoid arthritis [15], cancer invasion and metas-
tasis  [16].  MMPs  are  required  for  the  extracellular 
matrix  remodeling  [17]  and  the  activities  of  MMPs 
depend on the balance of their activators and inhibi-
tors,  and  balanced  gelatinase  activity  can  mediate 
endometrial remodeling [18,19]. MMPs and collagen 
might influence the development of adenomyosis [20] 
and  leiomyoma  [21].  Estrogen  might  stimulate  the 
collagen biosynthesis and modulates MMPs activity 
in  uterine  leiomyoma,  which  further  contributes  to 
the  development  of  leiomyoma  [21].  Activity  of 
MMPs was significantly higher in leiomyomas than 
that  in  myometrium,  which  suggests  its  roles  upon 
uterine neoplasm [22]. Compromised MMPs and col-
lagen  synthesis  are  associated  with  leiomyoma  cell 
growths in-vitro [23].  
Understanding the balance between MMPs ac-
tivity  and  collagen  metabolism  in  post-menopausal 
women  might  open  new  strategies  for  therapeutic 
interventions for uterine modeling and neoplasm. To 
the  best  of  our  knowledge,  no  investigators  have 
demonstrated the effects of diosgenin administration 
upon the uterine MMP and collagen expressions in 
menopausal  individuals.  Only  few  investigators 
demonstrated the effects of diosgenin treatment upon 
MMP or collagen expression in tumor cells [24] and 
leukemia disorders [25]. The aim of this study was to 
describe  the  effects  of  diosgenin  supplementation 
upon the  mRNA expression and activity of MMP-2 
and -9, and collagen in the myometrial tissue of rats 
after OVX.  
Materials and Methods 
Experimental animals and treatments 
Seven-week old female Wistar rats (245 ± 2 g; n = 
48; BioLASCO Taiwan Co., Ltd., Taiwan) were housed 
in groups of three in acrylic cages (35 × 56 × 19 cm) in 
an animal room with a 12 h light/dark cycle (lights on 
at 7:00 am) with food and water provided ad libitum. 
All  experimental  procedures  were  performed  ac-
cording to  the NIH  Guide for the Care and Use  of 
Laboratory Animals. All survey procedures were ap-
proved  by  the  Animal  Care  Committee  of  Chung 
Shan Medical University (IACUC approval No. 273). 
The procedure used for OVX was performed as 
previously described [26]. Briefly, the rats were anes-
thetized by means of the intraperitoneal injection of 2 
mg/kg of Zoletil 50 (Virbac, France) and the ovaries 
were retracted and removed. Immediately following 
surgery, each rat was injected with Penicillin-G pro-
caine (20,000 IU, i.m.). The sham-operated group un-
derwent the same surgical procedure except for the 
removal of the ovaries. After surgery, the rats were 
kept individually in acrylic cages for recovery for 7 
days, and then regrouped in their home cages. 
Diosgenin administration 
Diosgenin purchased from Sigma (St. Louis, MO, 
USA) was wrapped in a ball of bread (about 1 g) and 
fed daily to each rat. Four weeks after OVX, the rats 
were given diosgenin (0, 10, 50, or 100 mg/kg/day) 
orally  for  8  weeks.  On  the  56th  day  after  diosgenin 
administration, the serum of animals was sampled for Int. J. Biol. Sci. 2011, 7 
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the measurements of progesterone (P4) and estradiol 
(E2) concentration. The rats were then sacrificed using 
CO2 and their uteruses (myometrium) were removed 
and frozen immediately (within 10 min) in liquid ni-
trogen and stored at -80°C until use for RNA or pro-
tein extraction.  
Measurements of estradiol and progesterone 
Concentrations of serum E2 and P4 were quanti-
fied  by  a  radioimmunoassay  method  [27]  using  a 
Delfia  assay  kit  (PerkinElmer  Life  and  Analytical 
Sciences, Wallac Oy, Turku, Finland) according to the 
supplier's recommendations. All samples were tested 
as duplicates within a single assay and the concentra-
tions of E2 and P4 were calculated according to the 
standard curves. 
Protein extraction and electrophoresis 
Protein extraction, electrophoresis, and Western 
blot were performed as previously described [28]. The 
myometrial tissue (200 mg) was homogenized in 1 ml 
of ice-cold lysis buffer containing 20 mM Tris-HCl, pH 
7.6,  1  mM  dithiothreitol,  200  mM  sucrose,  1  mM 
EDTA, 0.1 mM sodium orthovanadate, 10 mM sodi-
um fluoride, 0.5 mM phenylmethylsulfonyl fluoride 
and  1%  (v/v)  Triton  X-100.  The  homogenates  were 
then centrifuged at 12,000  g for 15 min at 4°C. Su-
pernatants were collected, and the protein concentra-
tion  was  determined  by  Bio-Rad  protein  assay  kit 
(Bio-Rad Laboratories, Hercules, CA, USA) with bo-
vine serum albumin as a standard.  
Gelatin zymography 
The MMP-2 and -9 activities in the myometrial 
homogenate  were  surveyed  by  a  gelatinase  zy-
mography  assay.  Zymography  was  performed  by 
using gelatin-containing gels as described by Chen et 
al.  [29].  Briefly,  30  g  of  uterus  homogenate  was 
mixed with 2 zymography sample buffer (0.125 M 
Tris-HCl, pH = 6.8, 20% [v/v] glycerol, 4% [w/v] SDS, 
0.005%  bromophenol  blue)  incubated  for  10  min  at 
room temperature, and then loaded into each lane of 
an  10%  sodium  dodecyl  sulfate  polyacrylamide  gel 
(SDS-PAGE)  containing  0.1  mg/ml  gelatin  (Sigma). 
Following electrophoresis, the gel was washed twice 
for 30 min in zymogram renaturing buffer (2.5% Tri-
ton X-100) with gentle agitation at room temperature 
to remove SDS, then incubated overnight at 37°C in 
reaction  buffer  (50  mM  Tris-HCl,  pH  7.4,  200  mM 
NaCl,  and  5  mM  CaCl2).  After  Coomassie  brilliant 
blue staining, gelatinase activities were identified as 
clear  zones  against  a  blue  background.  Gelatinase 
activities in the gel slabs were quantified using Scion 
Image  software  (NIH,  Bethesda,  MD,  USA),  which 
quantifies  the  extent  of  lysis  in  bands  containing 
gelatinase.  A  MMP-2  or  -9  positive  controls 
(Chemicon, Temecula, CA, USA) was loaded in each 
gel  as  a  standard  to  normalize  density  values,  and 
band intensities are expressed in arbitrary units.  
Western blotting 
An amount of 20 µg of protein extract of each 
sample separated by SDS-PAGE was electrophoreti-
cally  transferred  to  polyvinylidene  fluoride  (PVDF) 
membranes  (Immobilon-PTM;  Millipore,  Bedford, 
MA, USA). After blocking, primary antibodies against 
collagen type I (anti-collagen type I, #ab6308; Abcam, 
Cambridge,  MA,  USA)  or  glyceralde-
hyde-3-phophate-dehydrogenase  (anti-GAPDH, 
#sc20357; Santa Cruz Biotechnology, Santa Cruz, CA, 
USA)  were  used  at  a  dilution  of  1:1,000,  and  the 
HRP-labeled  secondary  antibody  against  goat  IgG 
(#sc2020;  Santa  Cruz  Biotechnology)  or  rabbit  IgG 
(#sc2004; Santa Cruz Biotechnology) was applied us-
ing a dilution of 1:2,000. Substrates were visualized 
using  ECL  western  blotting  detection  reagents  ac-
cording to the  manufacturer’s instructions (Western 
LightningTM  Chemiluminescence  Reagent  Plus; 
PerkinElmer, Boston, MA, USA) and subsequent ex-
posure  of  the  membranes  to  X-ray  film  (Super  Rx 
Medical  X-Ray  Film;  Fujifilm,  Kanagawa,  Japan). 
Band  intensity  was  quantified  using  densitometric 
analysis  by  imaging  software  (ImageJTM;  National 
Institute of Mental Health, Bethesda, MD, USA). The 
amounts of collagen type I were expressed relative to 
the amount of GAPDH in respective samples. 
RNA extraction 
Total cellular RNA extraction from the myome-
trial tissues and RNA quantification were performed 
according to our previous report [28]. In brief, 200 mg 
of  uterus  tissue  was  homogenized  on  ice  by  a  ro-
tor-stator-type tissue homogenizer in 1 ml TRIzol re-
agent (GIBCO BRL, Gaithersburg, MD, USA). Cellular 
debris was removed by centrifugation for 10 min at 
12,000  g at 4C. RNA was precipitated by adding 
equal volumes of isopropanol and then washing with 
75% ethanol. The resultant RNA was further purified 
with  the  RNeasy  Midi  kit  (Qiagen,  Valencia,  CA, 
USA)  according  to  the  manufacturer’s  instructions. 
The  amount  of  total  RNA  was  determined  spectro-
photometrically at 260 nm, and the integrity was con-
firmed by analysis on a denaturing agarose gel.  
Semi-quantitative reverse transcrip-
tion-polymerase chain reaction (RT-PCR) 
The mRNA expressions of MMP-2 and -9 in the 
myometrium were surveyed by RT-PCR according to Int. J. Biol. Sci. 2011, 7 
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the procedure reported by Lin et al. [30]. For cDNA 
synthesis, five g RNA was reverse-transcribed in a 
total reaction volume of 20 l with 1 reverse tran-
scription  buffer,  0.5  mM  dNTPs,  2.5  M  oligo-dT 
(TOYOBO,  Osaka,  Japan),  1  U/l  RNase  inhibitor 
(TOYOBO), and 5 U/l ReverTra Ace reverse tran-
scriptase  (TOYOBO).  After  reaction  for  60  min  at 
42°C, the mixture was incubated for 5 min at 95°C to 
denature  the  cDNA  products.  RT-PCR  primers  and 
conditions are shown in Table 1. The PCR reactions 
contained 2 l cDNA, 3 l each primer (10 M), 5 l of 
10 PCR buffer, 2 l of 10 mM dNTPs, 1 l of 5 U/l 
Taq polymerase (Promega, Madison, WI, USA), and 
35 l distilled water in a total volume of 50 l. Ther-
mal cycler (MiniCycler
; MJ Research, Waltham, MA, 
USA) condition for each gene amplification is shown 
in  Table  1.  For  the  semi-quantitative  RT-PCR,  the 
number of cycles for each gene was optimized to en-
sure that the reaction was within the linear amplifica-
tion  range  (data  not  shown).  The  resulting  RT-PCR 
products were visualized on 1.5% agarose gels stained 
with SYBR Safe DNA gel stain (Invitrogen, Eugene, 
OR,  USA).  The  stained  image  was  recorded  by  an 
image  analyzer  (Kodak  DC290  Digital  camera  Sys-
tem;  Eastman  Kodak,  Rochester,  NY,  USA).  Band 
intensity of PCR DNA was quantified using densito-
metric analysis by Scion image. The relative mRNA 
expression  of  MMP-2  and  -9  were  normalized  to 
GAPDH expression. 
Statistical analysis 
To analyse the effects of surgery and diosgenin 
treatment,  two-way  analysis  of  variance  (ANOVA) 
was carried out. When interactions existed, the inde-
pendent t-test was used to analyze the effects of OVX 
procedures.  To  evaluate  the  effects  of  diosgenin 
treatment,  one-way  ANOVA  was  performed,  fol-
lowed by the least significant difference (LSD) post 
hoc test. All results are expressed as the mean ± SEM. 
The level of significance was defined as p-value < 0.05. 
 
Results 
Effects of OVX and diosgenin on BW 
During  the  experimental  period  of  8  weeks,  a 
trend  of  higher  BW  in  OVX  animals  compared  to 
Sham-operated  animals  was  observed  (Table  2).  In 
OVX rats, 4-weeks diosgenin supplements (10, 50, and 
100  mg/kg/day)  significantly  increased  BW  com-
pared  to  Sham  rats  with  similar-dosage  diosgenin 
supplementation  (p  <  0.05).  We  also  observed  the 
non-significantly  difference  of  BW  between  the  dif-
ferent dosage of diosgenin supplementation in both 
groups.  There  were  no  obvious  side  effects  in  the 
animals  after  diosgenin  administration  during  our 
experiment. 
Effects of OVX and diosgenin on reproductive 
hormones 
Lower  serum  P4  and  E2  concentrations  were 
observed  in  OVX  rats  compared  to  Sham  rats  (p < 
0.05). In the groups without diosgenin supplementa-
tion,  serum  P4  and  E2  concentrations  in  OVX  rats 
were 43% (p < 0.01) and 78% (p < 0.05) lower than 
those determined in Sham rats, respectively (Figure 
1A and 1B). In Sham rats, diosgenin supplementation 
increased serum P4 but not E2 concentrations. The P4 
concentration in Sham rats supplied with high dosage 
diosgenin  (100  mg/kg/day)  was  significantly  in-
creased  by  56%  (p  <  0.05)  compared  to  Sham  rats 
without  diosgenin  supplementation.  However,  the 
effect  of  diosgenin  supplementation  on  increasing 
serum P4 in OVX rats was not observed (Figure 1A). 
There  was  no  effect  of  diosgenin  on  serum  E2  ob-
served in OVX groups (Figure 1B).  
 
Table 1. The PCR primer sequences, protocols, and product sizes for MMP-2, MMP-9, and GAPDH used to assay gene 
expression by RT-PCR.  
Gene  Accession no.  Forward/Reverse primers sequence (5’→3’)  PCR amplification protocol (cycle no.)  PCR product 
size (bp) 
MMP-2  NM_031054  F-GTCCTGACCAAGGATATAGCC 
R-AGACCCAGTACTCATTCCCTG 
94°C, 5 min → [94°C, 30 sec → 55°C, 30 sec 
→ 72°C, 45 sec] (30) → 72°C, 3 min 
465 
MMP-9  U24441  F-GCTGCACCACCTTACCGGCCCTTTTATTTA 
R-TGGTTATCCTTCCACTGAGGGATCATCTCG 
94°C, 5 min → [94°C, 30 sec → 61°C, 30 sec 
→ 72°C, 45 sec] (40) → 72°C, 3 min 
458 
GAPDH  AF_261085  F-TGGCGCTGAGTACGTCGTG 
R-TTCAGCTCAGGGATGACCTT 
94°C, 5 min → [94°C, 30 sec → 56°C, 30 sec 
→ 72°C, 45 sec] (20) → 72°C, 3 min 
413 
MMP-2: matrix metalloproteinase-2; MMP-9: matrix metalloproteinase-9; GAPDH: glyceraldehyde-3-phophate dehydrogenase 
For the accuracy quantitative RT-PCR, the number of cycles for each gene has been optimized to ensure that the reaction is within the linear 
amplification range (data not shown). 
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Table 2. Comparisons of body weight between Sham controls and ovariectomized (OVX) rats during 8-week diosgenin 
administration (0, 10, 50, or 100 mg/kg/day).  
Body weight (g)  1 week  2 week  3 week  4 week  5 week  6 week  7 week  8 week 
Sham rats (n=24)                 
0 mg/kg/day  253 ± 14  263 ± 12  273 ± 15  289 ± 6  289 ± 21  293 ± 11  294 ± 13  299 ± 33 
10 mg/kg/day  252 ± 12  257 ± 17  275 ± 13  278 ± 5  282 ± 22  285 ± 25  278 ± 23  292 ± 30 
50 mg/kg/day  238 ± 12  251 ± 21  260 ± 15  270 ± 5  272 ± 30  278 ± 26  281 ± 20  288 ± 26 
100 mg/kg/day  253 ± 8  267 ± 18  277 ± 17  283 ± 12  283 ± 27  291 ± 28  290 ± 23  297 ± 24 
OVX rats (n=24)                 
0 mg/kg/day  253 ± 8  271 ± 15  296 ± 11  307 ± 12  308 ± 28  319 ± 26  319 ± 23  327 ±22 
10 mg/kg/day  251 ± 11  269 ± 18  305 ± 15  317 ± 11*  322 ± 32**  328 ± 27**  338 ± 26**  343 ± 24** 
50 mg/kg/day  256 ± 13  280 ± 29*  308 ± 14**  313 ± 13**  315 ± 36**  323 ± 29**  323 ± 38*  331 ± 27** 
100 mg/kg/day  246 ± 9  268 ± 15  293 ± 12  308 ± 8*  313 ± 36*  322 ± 26*  323 ± 27*  330 ± 25* 
* p < 0.05 and ** p < 0.01 compared to the parallel Sham rats 
 
 
 
 
Figure 1. Comparisons of progesterone and estradiol concentrations between controls (Sham) and ovariectomized 
(OVX) rats after diosgenin supplementation (0, 10, 50, and 100 mg/kg/day). The serum estradiol (E2) and proges-
terone (P4) concentrations were measured in duplicate aliquots of each sample. Bar graphs of all values were ex-
pressed as the mean ± SEM from six subjects. * p < 0.05 and ** p < 0.01 vs. the Sham groups; † p < 0.05 vs. Diosgenin-0 
in the same group.  
 
Effects of OVX and diosgenin on serum calcium, 
phosphorous and glucose level 
 The blood glucose level in OVX group was sig-
nificantly higher than that in Sham group (153  18 vs. 
128    20  mg/dl;  p <  0.05).  The  serum  calcium  and 
phosphorous  levels  were  10.5    0.5  and  7.3    0.6 
mg/dl in sham-operated rats, and 10.4  0.6 and 7.5  
0.7 in OVX rats, respectively. The findings indicated 
that  OVX  surgery  could  not  induce  a  significant 
change on serum calcium and phosphorous levels of 
OVX  rats.  Diosgenin  supplementation  also  had  no 
effect on serum calcium and phosphorous levels (p > 
0.05).The blood glucose levels were ranging from 115 
to 140 mg/dl in Sham groups and from 120 to 148 
mg/dl in OVX groups supplied with 10, 50 and 100 
mg/kg/day diosgenin with no significant differences 
observed in both OVX rats and Sham rats (p > 0.05).  Int. J. Biol. Sci. 2011, 7 
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Effects of OVX and diosgenin on MMP-2 activity 
and expression 
In order to understand the effects of OVX and 
diosgenin supplement upon the expression and activ-
ity of gelatinases in myometrial tissues, we estimated 
the myometrial MMP-2 activity by gelatin zymogra-
phy  (Figure  2A)  and  gene  expression  by 
semi-quantitative  RT-PCR  (Figure  3A).  The  results 
illustrate significantly lower MMP-2 activity (Figure 
2B) and also gene expression (Figure 3B) in OVX rats 
compared in Sham rats.  
  
 
 
 
Figure 2. Comparisons of MMP-2 activity between con-
trols (Sham) and ovariectomized (OVX) rats after dios-
genin supplementation (0, 10, 50, or 100 mg/kg/day). 
(A),  MMP-2  activity  was  determined  by  gelatin  zy-
mography  assay.  The  molecular  weight  of  MMP-2  de-
tected is approximately 72 kDa shown on the gel. The 
bands of enzymatic activity shown are representatives 
of six identical determinations. (B), the relative MMP-2 
activity  affected  by  ovariectomization  and  diosgenin 
treatment was assayed. Bar graphs of all values were 
expressed as the mean ± SEM from six subjects. ** p < 
0.01 vs. the Sham group; ‡ p < 0.01 vs. Diosgenin-0 in the 
same group. 
 
 
Figure  3.  Comparisons of  MMP-2 gene expression be-
tween controls (Sham) and ovariectomized (OVX) rats 
after  diosgenin  supplementation  (0,  10,  50,  or  100 
mg/kg/day).  (A),  MMP-2  gene  expression  was  deter-
mined by semi-quantitative RT-PCR. The length of the 
PCR products for MMP-2 and GAPDH were 456 bp and 413 
bp,  respectively.  Amplification  of  GAPDH  was  deter-
mined  as  an  internal  control.  The  bands  of  PCR  DNA 
shown are representatives of six identical determina-
tions. (B), the relative MMP-2 gene expression affected 
by ovariectomization and diosgenin treatment was as-
sayed. Bar graphs of all values were expressed as the 
mean ± SEM from six subjects. ** p < 0.01 vs. Sham group; 
† p < 0.05 vs. Diosgenin-0 in the same group. 
 
In the groups without diosgenin supplement, the 
relative MMP-2 activity and gene expression in OVX 
group was significantly reduced to 40% (p < 0.01) and 
38% (p < 0.01) of those detected in Sham groups. In 
OVX  rats,  regardless  of  diosgenin  dosage,  MMP-2 
activity and expression were still significantly lower 
than those of Sham groups (p < 0.05). Among OVX 
rats,  administration  of  high-dosages  (100 
mg/kg/day) of diosgenin supplementation increased 
both MMP-2 activity (Figure 2B) and gene expression 
(Figure 3B) compared to OVX rats without diosgenin Int. J. Biol. Sci. 2011, 7 
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supplementation  (p  >  0.05).  In  contrast,  diosgenin 
supplementation did not significantly influence my-
ometrial MMP-2 activity (Figure 2B) or gene expres-
sion (Figure 3B) in Sham rats (p > 0.05). 
Effects of OVX and diosgenin on MMP-9 activity 
and expression 
The effects of OVX and diosgenin on myometrial 
MMP-9 activity and expression were also determined 
by  gelatin  zymography  (Figure  4A)  and 
semi-quantitative RT-PCR (Figure 5A), respectively. 
 
 
 
 
Figure 4. Comparisons of MMP-9 activity between con-
trols (Sham) and ovariectomized (OVX) rats after dios-
genin supplementation (0, 10, 50, or 100 mg/kg/day). 
(A),  MMP-9  activity  was  determined  by  gelatin  zy-
mography  assay.  The  molecular  weight  of  MMP-9  de-
tected is approximately 95 kDa shown on the gel. The 
bands of enzymatic activity shown are representatives 
of six identical determinations. (B), the relative MMP-9 
activity  affected  by  ovariectomization  and  diosgenin 
treatment was assayed. Bar graphs of all values were 
expressed as the mean ± SEM from six subjects. ** p < 
0.01 vs. Sham group ; † p < 0.05 and ‡ p < 0.01 vs. Di-
osgenin-0 in the same group. 
 
Figure  5.  Comparisons of  MMP-9 gene expression be-
tween controls (Sham) and ovariectomized (OVX) rats 
after  diosgenin  supplementation  (0,  10,  50,  or  100 
mg/kg/day).  (A),  MMP-9  gene  expression  was  deter-
mined by semi-quantitative RT-PCR. The length of the 
PCR products for MMP-9 and GAPDH were 458 bp and 413 
bp,  respectively.  Amplification  of  GAPDH  was  deter-
mined  as  an  internal  control.  The  bands  of  PCR  DNA 
shown are representatives of six identical determina-
tions. (B), the relative MMP-9 gene expression affected 
by ovariectomization and diosgenin treatment was as-
sayed. Bar graphs of all values were expressed as the 
mean  ±  SEM  from  six  subjects.  **  p  <  0.01  vs.  Sham 
groups; † p < 0.05 vs. Diosgenin-0 in the same group. 
 
 
Similar  to  myometrial  MMP-2,  significantly 
lower MMP-9 activity (Figure 4B) and gene expres-
sion (Figure 5B) were observed in OVX rats compared 
to Sham rats (p < 0.05). In the groups without dios-
genin  supplement,  the  relative  MMP-9  activity  and 
gene expression in OVX group were significantly re-
duced to 50% (p < 0.01) and 49% (p < 0.01) of those in 
Sham group. In OVX rats, diosgenin supplementation 
(10, 50, and 100 mg/kg/day) significantly decreased 
MMP-9  activity  (Figure  4B)  and  gene  expression Int. J. Biol. Sci. 2011, 7 
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(Figure 5B) compared to OVX rats without diosgenin 
supplementation.  In  Sham  rats,  higher  dosages  (50 
and 100 mg/kg/day) of diosgenin supplementation 
also significantly decreased the MMP-9 activity and 
gene expression compared to those detected in Sham 
rats  without  diosgenin  supplementation  (p  <  0.05; 
Figure 4B and 5B). 
Effects of OVX and diosgenin on collagen ex-
pression 
Western  blots  were  used  to  determine  type  I 
collagen expression in myometrial tissues affected by 
OVX and diosgenin treatments, (Figure 6A).  
 
 
Figure  6.  Comparisons  of  type  I  collagen  expression 
between controls (Sham) and ovariectomized (OVX) rats 
after diosgenin treatment (0, 10, 50, or 100 mg/kg/day). 
(A),  collagen  expression  was  determined  by  Western 
blotting  assay.  The  molecular  weight  of  collagen  de-
tected  is  approximately  72  kDa.  The  Western  blots 
shown are representatives of six identical determina-
tions. (B), the relative collagen expression affected by 
ovariectomization and diosgenin treatment was assayed. 
Bar graphs of all values were expressed as the mean ± 
SEM from six subjects. * p < 0.05 and ** p < 0.01 vs. Sham 
groups; † p < 0.05 vs. Diosgenin-0 in the same group. 
The results show a higher collagen expression in 
OVX rats compared to Sham rats (p < 0.05; Figure 6B). 
Relative  collagen  expression  in  OVX  rats  was  in-
creased approximately 248% (p < 0.01) compared to 
sham-operated controls. Collagen expression in OVX 
rats supplied with 10, 50 and 100 mg/kg/day dios-
genin was reduced to be 93%, 73% (p < 0.05) and 65% 
(p < 0.05) of that determined in OVX rats without di-
osgenin  supplementation,  respectively.  In  contrast, 
diosgenin administrations did not significantly affect 
myometrial collagen expression in Sham rats (p > 0.05; 
Figure 6). 
Discussion 
MMPs are important in endometriotic tissue in-
vasion  and  angiogenesis  [31].  It  was  reported  that 
MMPs are critical modulators of endothelia-mediated 
vasoconstriction  in  estrogen  deficient  animals. 
Through complex and obscure mechanism, estrogen 
replacement leads to acute MMP modulation of vas-
cular function [32]. HRT with estrogen and proges-
terone might affect the MMPs expression of vascular 
smooth muscle cells via specific mechanisms and may 
lead  to  unbalanced  MMPs  regulation  [33].  Stromal 
gelatinases  expression  was  significantly  higher  in 
premenopausal polyps compared to postmenopausal 
polyps [34].  
Gelatinases, including MMP-2 and -9, play cen-
tral roles in the degradation of the extracellular matrix 
proteins, and are associated with numerous gyneco-
logical disorders, including adenomyosis [20], endo-
metriosis  [35],  and  endometrioid  endometrial  carci-
noma [36]. MMP-9 is associated with endometriosis 
pathways and is vital for normal uterine physiology 
[37], whereas abnormal MMP-9 expression is associ-
ated with uterine disorder [38]. MMP-2 is one major 
factor involved in the invasion of endometrium and 
vascularization of endometriosis [39]. MMP-2 and -9 
are also correlated with the processes of tumor cell 
invasion and metastasis in uterine neoplasms, which 
might  be  implicated  in  the  development  of  uterine 
leiomyoma [40].  
OVX  rats  are  used  as  a  menopausal  animal 
model,  because  the  biochemical  and  physiological 
changes that occur with the removal of rat ovaries are 
comparable to those observed in menopausal women 
[26, 41]. OVX animals showed a significant decrease in 
the gelatinolytic activities and expression of MMP-2 
and -9, and types I and III collagens in alveolar gran-
ulation  tissue  [42].  In  OVX  rats,  decreased  MMP-2 
gelatinolytic activity has been described during skin 
wound healing [43]. Despite the importance of MMP 
family  in  uterus,  regulation  and  molecular  mecha-
nisms  of  these  proteases  are  poorly  understood.  In Int. J. Biol. Sci. 2011, 7 
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this study, we demonstrate the interactions of dios-
genin  and  OVX  upon  MMP-2  and  -9  expressions 
within uterus. It is demonstrated that OVX could re-
duce MMP-2 activity and produced deleterious effects 
mimicking  menopause  intrinsically  [44].  Similar  to 
previous studies [42- 44], our results show a decline in 
the  activity  and  gene  expression  of  myometrial 
MMP-2 and -9 in OVX rats. Moreover, our findings 
indicate the potential roles of diosgenin upon MMP, 
collagen  and  uterine  regulation.  High  dose  supple-
ment  of  diosgenin  increased  MMP-2  and  inhibited 
MMP-9 activities/gene expressions in OVX rats. OVX 
also increased type I collagen expression in myome-
trial tissue as compared to Sham controls; however, 
which was reduced with diosgenin treatment.  
MMP-2 has been demonstrated to be associated 
with  the  endometrial  invasion  and  vascularization 
[39].  Therefore,  it  is  logical  to  observe  that  admin-
istration  of  diosgenin increases  the MMP-2 activity, 
which further stimulates the endometrial growth. In 
contrast, we also observed the inhibition of MMP-9 
activity and gene expression following diogenin ad-
ministration.  This  finding  was  compatible  with  the 
observation  of  Shishodia  and  Aggarwal  [24],  who 
demonstrated  that  diosgenin  administration  could 
downregulate  the  MMP-9  expression  in  cell  lines, 
human myeloid KBM-5 cells and mouse macrophage 
Raw  264.7  cells.  Another  similar  effect  of  estrogen 
supplement  upon  MMP-9  activity  was  reported  by 
Seeger  et  al.  [45],  who  demonstrated  that  estrogen 
supplement  would  decrease  the  MMP-9  activity  in 
MCF-7 cells, a human estrogen and progesterone re-
ceptor-positive human breast cancer cell line.  
Enhanced  understanding  of  MMP  regulation 
might lead to the establishment of therapies for the 
uterine disorders. A recent review of the MEDLINE 
database failed to produce studies that deal directly 
with  diosgenin  administration  upon  uterine  MMPs 
expression  in  the  menopausal/OVX  uterus.  In  this 
study,  our  findings  highlight  the  linkage  between 
diosgenin, MMP-2, -9 and type I collagen. The results 
suggest  that  the  absence  of  ovarian  hormones  after 
OVX might contribute to the abnormal uterine func-
tion by interfering with the extracellular matrix pro-
tein turnover, and might change the balance of MMP 
activity  and  collagen  metabolism.  These  findings 
suggest that diosgenin administration plays a role in 
gelatinase expression and activity, which were asso-
ciated with the uterus function of menopausal indi-
viduals.  However,  the  thorough  understanding  of 
MMP expressions in the uterus has yet to be accom-
plished.  Further  studies  are  necessary  to  clarify  the 
mechanisms of MMP production and activation in the 
uterine tissue. 
In the present study, we observed that the rela-
tive influences of diosgenin on decreasing MMP-9 are 
dose-dependent (10, 50, and 100 mg/kg/day) and a 
high  dosage  (100  mg/kg/day)  of  diosgenin  admin-
istration could increase  uterine MMP-2 activity and 
gene expression in OVX rats. We also observed that 
the increased type I collagen expression in myometri-
al tissue of OVX rats could be reduced with diosgenin 
treatment. The result hints that the OVX status might 
be partially mended with diosgenin treatment upon 
the regulation of collagen  expression.  In this study, 
the increasing serum P4 was observed in Sham rats, 
but not in OVX rats with  diosgenin administration. 
We do not think that the increasing serum P4 in rats is 
directly converted from diosgenin intake, because the 
lack  of  evidence  that  human  body  can  metabolize 
diosgenin into progesterone, aldosterone, cortisol or 
estrogen. This may explain why the serum estrogen in 
Sham and OVX rats with diosgenin treatment is sim-
ilar.  
In  this  study,  we  observed  that  higher  BW  in 
OVX rats across the 8 weeks post surgery, although 
no significant differences were noted among OVX or 
Sham rats with diosgenin supplements. Administra-
tion of large-dosage diosgenin increased the ovarian 
hormone concentrations in OVX rats. These findings 
suggest the potential of diosgenin administration to 
restore  gonadal  hormones  in  OVX  or  menopausal 
individuals [10]. High doses of diosgenin can influ-
ence the regulation of gelatinase and collagen metab-
olism in OVX rats. It suggested that diosgenin sup-
plement might modulate the gelatinase expression of 
menopause  status.  Abnormal  glucose  tolerance  and 
metabolism have been demonstrated to be associated 
with  menopausal  status  [46].  Serum  calcium  and 
phosphate are thought to be the associated marker of 
menopausal osteoporosis  [47, 48].  In this study, we 
adopted  these  three  serum  markers  to  detect  their 
association with OVX status. We observed that higher 
serum glucose concentration, but not serum calcium 
and phosphorous levels, was associated with the OVX 
status. The discrepancy between the results observed 
in our OVX rats and clinical studies of menopause are 
likely attributed to differences in species, age of sub-
jects, and in some cases disease status. 
In conclusion, this study highlights the correla-
tions between diosgenin supplement and  gelatinase 
expression in OVX rats, a model of the menopausal 
state. Diosgenin supplementation can alter expression 
and activity of gelatinases in the uterine tissue of OVX 
rats. Adequate diosgenin supplement might regulate 
ovarian  hormone  statuses  of  OVX  and  menopause 
statuses. However, the underlying mechanism of the Int. J. Biol. Sci. 2011, 7 
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interaction between diosgenin and MMPs in the uterus 
merits further survey.  
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